Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
NCT Number: NCT01563107
Patients with Postural Tachycardia Syndrome (POTS) may not adequately expand their plasma volume in response to a high sodium diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine (DA), may be impaired in POTS and may respond inappropriately to changes in dietary sodium. The investigators propose that the changes in urinary sodium and dopamine excretion caused by consuming low-sodium and high-sodium diets will be different between patients with POTS and healthy volunteers. The purpose of this study is to determine (1) whether changes in dietary sodium level appropriately influence sodium excretion in POTS; (2) whether changes in dietary sodium level appropriately influence DA excretion in POTS; (3) whether a high dietary sodium level appropriately expands plasma volume in POTS; and (4) whether patients with POTS have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.
Looking for future studies?
Notify Me18 year–50 year
Female
Interventional
Not applicable
Nashville, Tennessee, 37232, United States
Study Day 1
Study Days 2-5
Study Day 6
Study Day 7
All procedures are repeated at least a month later with the 2nd level of dietary salt. (Randomized to high or low salt in the first phase, the second phase is the remaining level)
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
Other names: DAXOR
subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
Other names: VO2 Max (maximal oxygen consumption)
Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Other names: Standing Orthostatic Challenge
Time frame: Day 6 am - Day 7 am for each dietary sodium level
Amount of sodium excreted in urine over 24hr ending on Day 7
Time frame: Between Day 6 am - Day 7 am of each dietary sodium level
Amount of dopamine excreted in urine over 24 hours ending on Day 7
Time frame: after 7 days of each dietary sodium level
Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions.
Time frame: Supine and upright heart rate were measured after 6 days of each dietary sodium level
Whether the magnitude of the heart rate increase that occurs in patients with POTS when moving from a supine to an upright position is attenuated by a High Sodium diet relative to a Low Sodium diet.
Heart rate was assessed after overnight rest and fasting after midnight, following at least 60 minutes of lying quietly. Heart rate was then measured at intervals after subjects had been standing for up to 30 minutes (as tolerated). Differences between supine and standing values are presented for 5 minutes standing (or maximal stand if <5 minutes) since several patients were unable to stand for 10 minutes.
Data in POTS patients were compared to that of Healthy Controls.
Time frame: Upright symptoms were assessed on the 6th day of low or high sodium diet.
Whether upright symptoms were improved in patients with POTS on a High Sodium diet relative to a Low Sodium diet.
Patients were asked to report their standing symptom burden at the end of the Stand portion of the posture study, using the Vanderbilt Orthostatic Symptoms Scale (VOSS). They rated the severity of nine symptoms (palpitations, lightheadedness, mental confusion, blurred vision, shortness of breath, tremulousness, chest discomfort, headache, and nausea) on a scale ranging from a minimum of 0 (reflecting an absence of symptoms) to a maximum score of 10. The sum of the individual symptom scores was used to calculate orthostatic symptom burden for each participant. The lowest possible total score was 0, if a participant scored all 9 questions as 0, and the highest possible score was 90, if a participant scored all 9 questions as 10. Higher scores indicated worse symptoms.
Time frame: 24 hour collections ending on Day 2 of each diet phase
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time frame: 24 hour collections ending on Day 2 of each dietary sodium phase
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time frame: 24 hour collections ending on Day 3 of each diet phase
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time frame: 24 hour collections ending on Day 4 of each diet phase
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time frame: 24 hour collections ending on Day 5 of each diet phase
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets
Time frame: 24 hour collections ending on Day 6 of each diet phase
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time frame: 24 hour collections ending on Day 3 of each dietary sodium phase
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time frame: 24 hour collections ending on Day 4 of each dietary sodium phase
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time frame: 24 hour collections ending on Day 5 of each dietary sodium phase
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time frame: 24 hour collections ending on Day 6 of each dietary sodium phase
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Vanderbilt University Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00962728
Arrhythmias, Cardiac, Autonomic Nervous System Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT02725060
Arrhythmias, Cardiac, Autonomic Nervous System Diseases
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT00608725
Arrhythmias, Cardiac, Autonomic Nervous System Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT06054958
Autonomic Nervous System Diseases, Chronic Fatigue Syndrome in Adolescence
Munich, Bavaria, Germany
View Trial Details